News
The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
Shares of Kura Oncology have plunged nearly 30% in premarket trading after the FDA placed a partial clinical hold on the company’s Phase Ib leukemia study following the report of a patient’s death.
The FDA approved Takeda’s Livtencity (maribavir) for adults and children 12 years or older with post-transplant cytomegalovirus (CMV) infection.
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.
A preprint in bioRxiv from Penn State showed SARS-CoV-2 was detected in 33% (94) of the 283 white-tailed deer tested in Iowa between November 23, 2020 and January 10, 2021.
Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.
Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022.
The U.S. FDA is making up for Covid-lost time this year, doubling the goal for FY 2021 domestic surveillance inspections for food and medical manufacturing facilities.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones from this week.